CN119386081A - A kind of active composition of lychee grass and its extraction method and application - Google Patents
A kind of active composition of lychee grass and its extraction method and application Download PDFInfo
- Publication number
- CN119386081A CN119386081A CN202411976326.8A CN202411976326A CN119386081A CN 119386081 A CN119386081 A CN 119386081A CN 202411976326 A CN202411976326 A CN 202411976326A CN 119386081 A CN119386081 A CN 119386081A
- Authority
- CN
- China
- Prior art keywords
- sage herb
- common sage
- supernatant
- active composition
- extraction method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000605 extraction Methods 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 244000183278 Nephelium litchi Species 0.000 title description 4
- 235000015742 Nephelium litchi Nutrition 0.000 title description 4
- 244000025254 Cannabis sativa Species 0.000 title 1
- 235000002020 sage Nutrition 0.000 claims abstract description 78
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 76
- 235000002912 Salvia officinalis Nutrition 0.000 claims abstract description 76
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000006228 supernatant Substances 0.000 claims abstract description 45
- 239000007788 liquid Substances 0.000 claims abstract description 30
- 210000004369 blood Anatomy 0.000 claims abstract description 29
- 239000008280 blood Substances 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 22
- 102000004190 Enzymes Human genes 0.000 claims abstract description 21
- 108090000790 Enzymes Proteins 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 21
- 239000002244 precipitate Substances 0.000 claims abstract description 18
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 17
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 230000005496 eutectics Effects 0.000 claims abstract description 16
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 230000001603 reducing effect Effects 0.000 claims abstract description 13
- 238000001556 precipitation Methods 0.000 claims abstract description 10
- 238000009210 therapy by ultrasound Methods 0.000 claims abstract description 9
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000003472 antidiabetic agent Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 108091005658 Basic proteases Proteins 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 3
- 235000019743 Choline chloride Nutrition 0.000 claims description 3
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 3
- 229960003178 choline chloride Drugs 0.000 claims description 3
- 239000003524 antilipemic agent Substances 0.000 claims description 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 6
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract description 3
- 229930186217 Glycolipid Natural products 0.000 abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 238000001914 filtration Methods 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000007873 sieving Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940126904 hypoglycaemic agent Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 241001071917 Lithospermum Species 0.000 description 2
- 241001072909 Salvia Species 0.000 description 2
- 235000017276 Salvia Nutrition 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical compound CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000003820 β-cell dysfunction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0288—Applications, solvents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a common sage herb active composition, an extraction method and application thereof, and belongs to the technical field of active ingredient extraction, wherein the extraction method comprises the following steps of S1, crushing common sage herb to obtain common sage herb powder; S2, adding eutectic solvent and water into common sage herb powder, performing ultrasonic treatment, performing solid-liquid separation to obtain supernatant A and residues, S3, adding compound enzyme into the residues for enzymolysis, performing solid-liquid separation to obtain enzymolysis liquid, S4, adding ethanol into the enzymolysis liquid for alcohol precipitation to obtain precipitate and supernatant B, S5, performing low-temperature extraction on the supernatant B obtained in the step S2 to obtain an extract, and S6, mixing the supernatant A obtained in the step S1, the precipitate obtained in the step S4 and the extract obtained in the step S5, adding cyclodextrin for concentration to obtain the common sage herb active composition. Experiments show that the common sage herb active composition prepared by the invention has the efficacy of reducing blood fat while reducing blood sugar, and realizes the synchronization of glycolipid.
Description
Technical Field
The invention relates to the technical field of active ingredient extraction, in particular to a common sage herb active composition, and an extraction method and application thereof.
Background
Type 2 diabetes accounts for 90% of total diabetes, and its main pathogenesis is insulin resistance, islet beta cell failure and insulin secretion disorder. Type 2 diabetes is often accompanied by obesity, hypertriglyceridemia or hypercholesterolemia, and hyperlipidemia is one of the major causes of insulin resistance and islet beta cell dysfunction. Diabetes can lead to a variety of acute and chronic complications, such as ketoacidosis, cardiovascular and cerebrovascular diseases, kidney diseases, etc., which pose a serious threat to human health. The existing common hypoglycemic agents comprise insulin, sulfonylurea drugs, non-sulfonylurea insulin secretagogues, biguanide hypoglycemic agents, insulin sensitizers and the like, and the hypoglycemic agents have the advantages of quick action, good curative effect, strong toxic and side effects, damage to organs such as liver and kidney and obvious drug resistance to insulin of partial diabetics. Diabetes is a life-long disease and needs to be taken for a long time, so that the discovery of new safe and effective antidiabetic drugs is an urgent need of the current society.
Common sage herb (Salvia plebaia R. Brown), also called Xueshen, is a plant belonging to the genus Salvia of Labiatae, and is first mentioned in Ben Cao gang mu, which has bitter and pungent taste, cool nature, enters stomach, lung and kidney meridians, leaves are contra-living, glandular spots are on the back, short hairs are spread on both sides, and is a two-year-old upright herb, and all herbs can be used as medicines. Researches show that the common sage herb contains active ingredients such as flavonoid, terpenes, phenylpropanoids, volatile oil, polysaccharide and the like, and has various pharmacological effects of resisting oxidation, bacteria, inflammation, viruses, livers and liver, relieving cough and asthma and the like.
Less research on active ingredients of common sage herb with blood sugar reducing function is carried out in the prior art, guo Chang and the like disclose that common sage herb crude polysaccharide obtained by adopting a water extraction method and an alkali extraction method has the activity of inhibiting alpha-amylase in common sage herb polysaccharide extraction process optimization and in vitro antioxidation and blood sugar reducing activity analysis (Guo Chang, li Chao, hou Mingming and the like).
The extraction process of the traditional Chinese medicine is closely related to the efficacy of the extracted active ingredients, the active ingredients with the blood sugar reducing effect prepared by the existing extraction method of the common sage herb are single, and the blood sugar reducing effect still has a larger improvement space.
Disclosure of Invention
In order to solve the technical problems, the invention provides a common sage herb active composition, and an extraction method and application thereof.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
In a first aspect, the present invention provides a method for extracting an active composition of common sage herb, comprising the steps of:
s1, crushing common sage herb to obtain common sage herb powder;
s2, adding a eutectic solvent and water into the common sage herb powder, performing ultrasonic treatment, and performing solid-liquid separation to obtain a supernatant A and residues;
s3, adding compound enzyme into the residue for enzymolysis, and carrying out solid-liquid separation to obtain enzymolysis liquid;
s4, adding ethanol into the enzymolysis liquid for alcohol precipitation to obtain a precipitate and a supernatant B;
s5, extracting the supernatant B obtained in the step S2 at a low temperature to obtain an extract;
s6, mixing the supernatant A obtained in the step S2, the precipitate obtained in the step S4 and the extract obtained in the step S5, adding cyclodextrin, and concentrating to obtain the common sage herb active composition.
Preferably, the particle size of the common sage herb powder in the step S1 is 60-120 meshes.
Preferably, the eutectic solvent in the step S2 consists of choline chloride and glycerol, and further preferably, the molar ratio of the choline chloride to the glycerol is 1:1-3.
Preferably, the mass volume ratio of the common sage herb powder, the eutectic solvent and the water in the step S2 is 1g (5-8) mL:2mL, and more preferably 1g:6mL:2mL.
Preferably, the condition of the ultrasonic wave in the step S2 is that the power is 100-500W, the temperature is 40-50 ℃ and the time is 30-60min, and further preferably 300W, the temperature is 45 ℃ and the time is 45min.
Preferably, the complex enzyme in the step S3 is pectase and alkaline protease, and more preferably, the mass ratio of pectase to alkaline protease is 3-6:1, and even more preferably, 4:1.
Preferably, the complex enzyme is added in an amount of 0.5 to 1.5% by mass of the residue in step S3.
Preferably, the enzymolysis condition in the step S3 is that the enzymolysis is carried out for 1-3 hours at the temperature of 30-40 ℃.
Preferably, the ethanol is added in the amount of 2-4 times, more preferably 3 times, the volume of the enzymatic hydrolysate in the step S4.
Preferably, the volume fraction of the ethanol is 70-95%.
Preferably, the alcohol precipitation in step S4 is performed at 0-4 ℃ for 12 hours or more, preferably 12-24 hours.
Preferably, the low-temperature extraction in the step S5 is carried out at the extraction temperature of 40-50 ℃ and the pressure of-0.04 to-0.02 MPa, and the extraction time is 2-4h.
Preferably, the cyclodextrin is added in step S6 in an amount of 0.2-0.8% of the total weight of supernatant a and extract.
Preferably, the concentration in step S6 is such that the relative density is 1.25-1.30 at 40-50deg.C.
In a second aspect, the present invention provides a composition of sage herb active obtained by the above extraction method.
In a third aspect, the present invention provides an application of the above-mentioned common sage herb active composition in preparing a hypoglycemic and hypolipidemic drug.
In a fourth aspect, the invention provides a medicament for reducing blood sugar and blood fat, which comprises the common sage herb active composition and pharmaceutically acceptable auxiliary materials.
The beneficial effects of the invention are as follows:
(1) The common sage herb active composition is prepared by improving the common sage herb extraction process and combining eutectic extraction, enzymolysis and low-temperature extraction, and compared with the existing extraction technology, the common sage herb active composition does not need purification treatment and has higher yield.
(2) Experiments show that the common sage herb active composition prepared by the invention has the efficacy of reducing blood fat while reducing blood sugar, and realizes the synchronization of glycolipid.
Detailed Description
The following examples are presented only to aid in understanding the method of the present invention and its core ideas. It should be noted that it will be apparent to those skilled in the art that various modifications and adaptations of the invention can be made without departing from the principles of the invention and these modifications and adaptations are intended to be within the scope of the invention as defined in the following claims. The following description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described herein.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The raw materials in this example are all common commercial products, and the purchase information of a part of the raw materials is shown in table 1.
TABLE 1 raw material information
Example 1 extraction method of a lychee active composition
The extraction method comprises the following steps:
S1, crushing common sage herb, and sieving the crushed common sage herb with a 80-mesh sieve to obtain common sage herb powder;
s2, mixing the common sage herb powder, the eutectic solvent and water according to the mass volume ratio of 1g to 6mL to 2mL, performing ultrasonic treatment at the temperature of 45 ℃ and 300W for 45min, and filtering (0.22 mu m acetic acid film) to obtain supernatant A and residues;
s3, adding water to the residues obtained in the step S2, wherein the adding amount of the water is 1 time of the mass of the residues, adding complex enzyme, wherein the adding amount of the complex enzyme is 1% of the mass of the residues, performing enzymolysis for 2 hours at 35+/-2 ℃, and filtering to obtain enzymolysis liquid;
S4, adding ethanol (volume fraction is 85%) into the enzymolysis liquid obtained in the step S3, wherein the addition amount of the ethanol is 3 times of the volume of the enzymolysis liquid, and performing alcohol precipitation for 12 hours at 2+/-2 ℃ to obtain a precipitate and a supernatant B;
s5, extracting the supernatant B obtained in the step S2 at a low temperature to obtain an extract;
S6, mixing the supernatant A obtained in the step S1, the precipitate obtained in the step S4 and the extract obtained in the step S5, adding cyclodextrin, mixing again uniformly, adding cyclodextrin in an amount of 0.5% of the total weight of the supernatant A and the extract, and concentrating at 45+/-2 ℃ until the relative density is 1.25-1.30, thus obtaining the common sage herb active composition.
The process parameters are shown in table 2.
TABLE 2 essential process parameters of the extraction method of example 1
Example 2 extraction method of a Lithospermum active composition
The extraction method comprises the following steps:
S1, crushing common sage herb, and sieving the crushed common sage herb with a 80-mesh sieve to obtain common sage herb powder;
s2, mixing the common sage herb powder, the eutectic solvent and water according to the mass volume ratio of 1g to 6mL to 2mL, performing ultrasonic treatment at the temperature of 45 ℃ and 300W for 45min, and filtering (0.22 mu m acetic acid film) to obtain supernatant A and residues;
s3, adding water to the residues obtained in the step S2, wherein the adding amount of the water is 1 time of the mass of the residues, adding complex enzyme, wherein the adding amount of the complex enzyme is 1% of the mass of the residues, performing enzymolysis for 2 hours at 35+/-2 ℃, and filtering to obtain enzymolysis liquid;
S4, adding ethanol (volume fraction is 85%) into the enzymolysis liquid obtained in the step S3, wherein the addition amount of the ethanol is 3 times of the volume of the enzymolysis liquid, and performing alcohol precipitation for 12 hours at 2+/-2 ℃ to obtain a precipitate and a supernatant B;
s5, extracting the supernatant B obtained in the step S2 at a low temperature to obtain an extract;
S6, mixing the supernatant A obtained in the step S1, the precipitate obtained in the step S4 and the extract obtained in the step S5, adding cyclodextrin, mixing again uniformly, adding cyclodextrin in an amount of 0.2% of the total weight of the supernatant A and the extract, and concentrating at 45+/-2 ℃ until the relative density is 1.25-1.30, thus obtaining the common sage herb active composition.
The process parameters are shown in table 3.
TABLE 3 essential process parameters of the extraction method of example 2
Example 3 extraction method of a Lithospermum active composition
The extraction method comprises the following steps:
S1, crushing common sage herb, and sieving the crushed common sage herb with a 80-mesh sieve to obtain common sage herb powder;
s2, mixing the common sage herb powder, the eutectic solvent and water according to the mass volume ratio of 1g to 6mL to 2mL, performing ultrasonic treatment at the temperature of 45 ℃ and 300W for 45min, and filtering (0.22 mu m acetic acid film) to obtain supernatant A and residues;
s3, adding water to the residues obtained in the step S2, wherein the adding amount of the water is 1 time of the mass of the residues, adding complex enzyme, wherein the adding amount of the complex enzyme is 1% of the mass of the residues, performing enzymolysis for 2 hours at 35+/-2 ℃, and filtering to obtain enzymolysis liquid;
S4, adding ethanol (volume fraction is 85%) into the enzymolysis liquid obtained in the step S3, wherein the addition amount of the ethanol is 3 times of the volume of the enzymolysis liquid, and performing alcohol precipitation for 12 hours at 2+/-2 ℃ to obtain a precipitate and a supernatant B;
s5, extracting the supernatant B obtained in the step S2 at a low temperature to obtain an extract;
S6, mixing the supernatant A obtained in the step S1, the precipitate obtained in the step S4 and the extract obtained in the step S5, adding cyclodextrin, mixing again uniformly, adding cyclodextrin in an amount of 0.8% of the total weight of the supernatant A and the extract, and concentrating at 45+/-2 ℃ until the relative density is 1.25-1.30, thus obtaining the common sage herb active composition.
The process parameters are shown in table 4.
TABLE 4 essential process parameters of the extraction method of example 3
Comparative example 1 extraction method of a lychee active composition
This comparative example differs from example 1 only in that the complex enzyme is different from the alpha-amylase instead of alkaline protease;
Specifically, the extraction method comprises the following steps:
S1, crushing common sage herb, and sieving the crushed common sage herb with a 80-mesh sieve to obtain common sage herb powder;
s2, mixing the common sage herb powder, the eutectic solvent and water according to the mass volume ratio of 1g to 6mL to 2mL, performing ultrasonic treatment at the temperature of 45 ℃ and 300W for 45min, and filtering (0.22 mu m acetic acid film) to obtain supernatant A and residues;
s3, adding water to the residues obtained in the step S2, wherein the adding amount of the water is 1 time of the mass of the residues, adding complex enzyme, wherein the adding amount of the complex enzyme is 1% of the mass of the residues, performing enzymolysis for 2 hours at 35+/-2 ℃, and filtering to obtain enzymolysis liquid;
S4, adding ethanol (volume fraction is 85%) into the enzymolysis liquid obtained in the step S3, wherein the addition amount of the ethanol is 3 times of the volume of the enzymolysis liquid, and performing alcohol precipitation for 12 hours at 2+/-2 ℃ to obtain a precipitate and a supernatant B;
s5, extracting the supernatant B obtained in the step S2 at a low temperature to obtain an extract;
S6, mixing the supernatant A obtained in the step S1, the precipitate obtained in the step S4 and the extract obtained in the step S5, adding cyclodextrin, mixing again uniformly, adding cyclodextrin in an amount of 0.5% of the total weight of the supernatant A and the extract, and concentrating at 45+/-2 ℃ until the relative density is 1.25-1.30, thus obtaining the common sage herb active composition.
The process parameters are shown in table 5.
TABLE 5 main process parameters of comparative example 1 extraction method
Comparative example 2 extraction method of a lychee active composition
This comparative example differs from example 1 only in that the eutectic solvent is different and malic acid is used instead of glycerol.
Specifically, the extraction method comprises the following steps:
S1, crushing common sage herb, and sieving the crushed common sage herb with a 80-mesh sieve to obtain common sage herb powder;
s2, mixing the common sage herb powder, the eutectic solvent and water according to the mass volume ratio of 1g to 6mL to 2mL, performing ultrasonic treatment at the temperature of 45 ℃ and 300W for 45min, and filtering (0.22 mu m acetic acid film) to obtain supernatant A and residues;
s3, adding water to the residues obtained in the step S2, wherein the adding amount of the water is 1 time of the mass of the residues, adding complex enzyme, wherein the adding amount of the complex enzyme is 1% of the mass of the residues, performing enzymolysis for 2 hours at 35+/-2 ℃, and filtering to obtain enzymolysis liquid;
S4, adding ethanol (volume fraction is 85%) into the enzymolysis liquid obtained in the step S3, wherein the addition amount of the ethanol is 3 times of the volume of the enzymolysis liquid, and performing alcohol precipitation for 12 hours at 2+/-2 ℃ to obtain a precipitate and a supernatant B;
s5, extracting the supernatant B obtained in the step S2 at a low temperature to obtain an extract;
S6, mixing the supernatant A obtained in the step S1, the precipitate obtained in the step S4 and the extract obtained in the step S5, adding cyclodextrin, mixing again uniformly, adding cyclodextrin in an amount of 0.5% of the total weight of the supernatant A and the extract, and concentrating at 45+/-2 ℃ until the relative density is 1.25-1.30, thus obtaining the common sage herb active composition.
The process parameters are shown in table 6.
TABLE 6 main process parameters of comparative example 2 extraction method
Comparative example 3 extraction method of an active composition of common sage herb
The comparative example differs from example 1 only in the composition ratio of the complex enzyme and the composition ratio of the eutectic solvent.
Specifically, the extraction method comprises the following steps:
S1, crushing common sage herb, and sieving the crushed common sage herb with a 80-mesh sieve to obtain common sage herb powder;
s2, mixing the common sage herb powder, the eutectic solvent and water according to the mass volume ratio of 1g to 6mL to 2mL, performing ultrasonic treatment at the temperature of 45 ℃ and 300W for 45min, and filtering (0.22 mu m acetic acid film) to obtain supernatant A and residues;
s3, adding water to the residues obtained in the step S2, wherein the adding amount of the water is 1 time of the mass of the residues, adding complex enzyme, wherein the adding amount of the complex enzyme is 1% of the mass of the residues, performing enzymolysis for 2 hours at 35+/-2 ℃, and filtering to obtain enzymolysis liquid;
S4, adding ethanol (volume fraction is 85%) into the enzymolysis liquid obtained in the step S3, wherein the addition amount of the ethanol is 3 times of the volume of the enzymolysis liquid, and performing alcohol precipitation for 12 hours at 2+/-2 ℃ to obtain a precipitate and a supernatant B;
s5, extracting the supernatant B obtained in the step S2 at a low temperature to obtain an extract;
S6, mixing the supernatant A obtained in the step S1, the precipitate obtained in the step S4 and the extract obtained in the step S5, adding cyclodextrin, mixing again uniformly, adding cyclodextrin in an amount of 0.5% of the total weight of the supernatant A and the extract, and concentrating at 45+/-2 ℃ until the relative density is 1.25-1.30, thus obtaining the common sage herb active composition.
The process parameters are shown in table 7.
TABLE 7 main process parameters of comparative example 3 extraction method
Efficacy verification
1. Experimental animal
Male SD rats, weighing 180-200g.
2. Experimental medicine
The sage herb active compositions prepared in examples 1 to 3 and comparative examples 1 to 3.
3. Experimental method
(1) Moulding
SD rats were randomly divided into model and normal control groups (8) according to body weight after 3 days of adaptive feeding. The model group was fed with high sugar and high fat feed (lard 10%, yolk powder 6%, sucrose 21%, cholesterol 2.0%, cholate 1% and normal feed 60%), and the normal control group was fed with normal feed. After 6 weeks of feeding, rats in the model group were intraperitoneally injected with Streptozotocin (STZ) 40mg/kg for 12 hours on an empty stomach, and the normal control group was injected with the same dose of citric acid (0.1 mol/L citric acid) as a control. After 2 weeks, rats were fasted for 12 hours, blood was taken and blood glucose was measured, and modeling was judged to be successful with 12 mmol/L < fasting blood glucose <17 mmol/L as a standard.
(2) Grouping and administration
Rats successfully molded are randomly divided into an experiment group S1-experiment group S3, an experiment group D1-experiment group D3 and a model control group according to fasting blood glucose, wherein 8 rats are respectively filled with the common sage herb active compositions prepared in the examples 1-3 and the comparative examples 1-3, the dosage is 10mg/kg, the common sage herb active compositions are filled with the common sage herb active compositions 1 times per day for 6 weeks, and the model control group and the normal control group are filled with equal volumes of physiological saline.
4. Detection index
At the end of the experiment, rats were sacrificed after 12h of fasted, anesthetized, and bled.
Fasting blood glucose test, namely sterilizing the tail tip with 75% medicinal alcohol, cutting the tail to obtain blood, and testing blood glucose with a blood glucose meter.
Blood lipid detection, namely taking blood from the heart, placing the heart in a 37 ℃ constant-temperature water bath box for water bath for 5 minutes, centrifuging at 3000rpm for 5 minutes, taking supernatant, and detecting total cholesterol TC and triglyceride TG by adopting a full-automatic biochemical analyzer.
The results are shown in tables 8 and 9.
Table 8 rat fasting blood glucose (mean.+ -. Standard deviation)
Note that the different letters in the same column represent significant differences in data between groups, P <0.05.
The results show that:
compared with the model control group, the fasting blood glucose of rats in the experimental group S1-the experimental group S3 is obviously reduced (P < 0.05), which indicates that the common sage herb active compositions extracted in the embodiment 1-the embodiment 3 have better blood glucose reducing effect.
Experimental group D1-experimental group D3, which were administered by intragastric administration at a dose of 10mg/kg for 6 weeks using the common sage herb active compositions extracted in comparative examples 1-3, showed that rats had no statistical difference (P > 0.05) in fasting blood glucose changes compared with the model control group, indicating that the common sage herb active compositions extracted in comparative examples 1-3 had no blood glucose regulating effect in the technical scheme of the present invention.
TABLE 9 serum Total cholesterol and Triglycerides (mean.+ -. Standard deviation) in rats
Note that the different letters in the same column represent significant differences in data between groups, P <0.05.
The results show that:
the rats in the model control group had significantly elevated serum total cholesterol and triglycerides (P < 0.05) compared to the normal control group, indicating that the high glycolipid diet can lead to elevated serum total cholesterol and triglycerides.
Compared with the model control group, the serum total cholesterol and triglyceride of rats in the experimental group S1-the experimental group S3 are obviously reduced (P < 0.05), which shows that the common sage herb active compositions extracted in the embodiment 1-the embodiment 3 have the efficacy of reducing blood fat.
Compared with a model control group, the experimental group D1-the experimental group D3 has no statistical difference (P > 0.05) between the total cholesterol and the triglyceride of the serum of the rats, which shows that the common sage herb active composition extracted in the comparative example 1-the comparative example 3 has no effect of reducing blood fat in the technical scheme of the invention.
The invention has been further described above in connection with specific embodiments, which are exemplary only and do not limit the scope of the invention in any way. It will be understood by those skilled in the art that various changes and substitutions of details and forms of the technical solution of the present invention may be made without departing from the spirit and scope of the present invention, but these changes and substitutions fall within the scope of the present invention.
Claims (10)
1. The extraction method of the common sage herb active composition is characterized by comprising the following steps of:
s1, crushing common sage herb to obtain common sage herb powder;
s2, adding a eutectic solvent and water into the common sage herb powder, performing ultrasonic treatment, and performing solid-liquid separation to obtain a supernatant A and residues;
s3, adding compound enzyme into the residue for enzymolysis, and carrying out solid-liquid separation to obtain enzymolysis liquid;
s4, adding ethanol into the enzymolysis liquid for alcohol precipitation to obtain a precipitate and a supernatant B;
s5, extracting the supernatant B obtained in the step S2 at a low temperature to obtain an extract;
s6, mixing the supernatant A obtained in the step S1, the precipitate obtained in the step S4 and the extract obtained in the step S5, adding cyclodextrin, and concentrating to obtain the common sage herb active composition;
The eutectic solvent in the step S2 is choline chloride and glycerol with a molar ratio of 1:1-3;
the complex enzyme in the step S3 is pectase and alkaline protease with the mass ratio of 3-6:1;
The low-temperature extraction in the step S5 is carried out at the extraction temperature of 40-50 ℃ and the pressure of-0.04 to-0.02 MPa, and the extraction time is 2-4h.
2. The extraction method according to claim 1, wherein the mass-to-volume ratio of the common sage herb powder, the eutectic solvent and the water in the step S2 is 1g, 5-8mL, 2mL.
3. The method according to claim 1, wherein the condition of the ultrasound in step S2 is 100-500W power, 40-50 ℃ temperature, and 30-60min time.
4. The extraction method according to claim 1, wherein the complex enzyme is added in an amount of 0.5-1.5% by mass of the residue in step S3.
5. The method according to claim 4, wherein the conditions for the enzymolysis in step S3 are 30-40deg.C for 1-3 hours.
6. The extraction method according to claim 1, wherein the cyclodextrin is added in an amount of 0.2-0.8% of the total weight of supernatant a and extract in step S6.
7. The extraction method according to claim 1, wherein the concentration in step S6 is performed at 40-50deg.C to a relative density of 1.25-1.30.
8. The active composition of common sage herb obtained by the extraction method according to any one of claims 1 to 7.
9. Use of the active composition of common sage herb according to claim 8 in the preparation of a hypoglycemic and hypolipidemic agent.
10. A medicament for reducing blood sugar and blood fat, comprising the common sage herb active composition of claim 8 and pharmaceutically acceptable auxiliary materials.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411976326.8A CN119386081A (en) | 2024-12-31 | 2024-12-31 | A kind of active composition of lychee grass and its extraction method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411976326.8A CN119386081A (en) | 2024-12-31 | 2024-12-31 | A kind of active composition of lychee grass and its extraction method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119386081A true CN119386081A (en) | 2025-02-07 |
Family
ID=94415604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411976326.8A Pending CN119386081A (en) | 2024-12-31 | 2024-12-31 | A kind of active composition of lychee grass and its extraction method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN119386081A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474251A (en) * | 2008-12-19 | 2009-07-08 | 华东理工大学 | Common sage herb total flavone extract as well as preparation method and application thereof |
| KR20170049922A (en) * | 2015-10-29 | 2017-05-11 | 대한민국(농촌진흥청장) | Pharmaceutical composition for preventing or treating thrombosis comprising an extract of Salvia plebeia |
| CN107459588A (en) * | 2017-09-29 | 2017-12-12 | 渤海大学 | A kind of supercritical CO2The method that fluid extraction technology extracts lichee grass polysaccharide |
| WO2020235917A1 (en) * | 2019-05-21 | 2020-11-26 | 한국 한의학 연구원 | Composition for alleviating or treating acne, comprising, as active ingredient, extract of salvia plebeia r. br. or fraction thereof |
-
2024
- 2024-12-31 CN CN202411976326.8A patent/CN119386081A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474251A (en) * | 2008-12-19 | 2009-07-08 | 华东理工大学 | Common sage herb total flavone extract as well as preparation method and application thereof |
| KR20170049922A (en) * | 2015-10-29 | 2017-05-11 | 대한민국(농촌진흥청장) | Pharmaceutical composition for preventing or treating thrombosis comprising an extract of Salvia plebeia |
| CN107459588A (en) * | 2017-09-29 | 2017-12-12 | 渤海大学 | A kind of supercritical CO2The method that fluid extraction technology extracts lichee grass polysaccharide |
| WO2020235917A1 (en) * | 2019-05-21 | 2020-11-26 | 한국 한의학 연구원 | Composition for alleviating or treating acne, comprising, as active ingredient, extract of salvia plebeia r. br. or fraction thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王继锋;颜娓娓;徐佳馨;郭浩;史晨晓;周长征;: "荔枝草的化学成分及药理作用研究新进展", 湖南中医药大学学报, no. 04, 29 May 2018 (2018-05-29) * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4353982B2 (en) | Synergistic composition for the treatment of diabetes | |
| CN101474211A (en) | Phellinus linteus extract and preparation method thereof | |
| US11384109B2 (en) | Method for separating phenolic acid glucoside compounds from Diaphragma juglandis Fructu | |
| CN102836188A (en) | Folium microcotis total flavone extract and preparation method and application thereof | |
| CN108524668A (en) | A kind of preparation method to wolfberry fruit extract of the drug induced hepatic injury with reparation and therapeutic effect | |
| CN117503887A (en) | Preparation method and application of total phenolic extract of grass and fruit | |
| CN112655967A (en) | Artemisia sphaerocephala essential oil microcapsule taking purslane extract as wall material and preparation method thereof | |
| CN119386081A (en) | A kind of active composition of lychee grass and its extraction method and application | |
| CN101683387B (en) | Medication and preparation method and application thereof | |
| CN116173085B (en) | Acanthopanax senticosus extract and preparation method and application thereof | |
| CN116114876B (en) | Hypoglycemic composition containing sugarcane polyphenol and chlamydomonas reinhardtii and preparation method thereof | |
| CN111248440A (en) | Functional jasmine flower oligosaccharide oral liquid and application thereof | |
| CN117462580A (en) | Uses of artichoke polyphenols | |
| CN1565467A (en) | Use of cornel and its extract in preparation alpha-glucosidase inhibitor medicine | |
| CN106822338B (en) | Compound composition for lowering blood sugar and blood lipid, preventing and/or treating diabetes and its complications and use thereof | |
| CN111920799A (en) | Kulecuo effective component composition and preparation method and application thereof | |
| CN108586632A (en) | A kind of asparagus polysaccharide and the preparation method and application thereof with notable hypolipidemic activity | |
| CN113679759A (en) | Application of a safflower seed extract in the preparation of a drug for preventing or treating non-alcoholic fatty liver disease | |
| KR101910099B1 (en) | Compositions for improving lipid metabolism or anti-obesity as an active ingredient extracted from an immature persimmon by pressurized hydrothermal method | |
| CN111700927A (en) | A kind of medicine and food homologous composition with hypoglycemic effect and its preparation method and application | |
| CN102319273A (en) | Salicornia biggelowii Torr. active total saponin extract, its preparation method and its purpose of losing weight | |
| CN118477155B (en) | A lipid-lowering and anti-obesity ginger notoginseng extract and its application | |
| CN103285113A (en) | Pharmaceutical composition for preventing and/or treating diabetes mellitus | |
| CN107334795A (en) | Application of the Chinese trumpet creeper general flavone as sole active agent in preparing treatment Streptozotocin and causing diabetes medicament | |
| CN113397016B (en) | Preparation method of dogwood and hawthorn table tea for reducing blood sugar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |